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1. IN’IXODUCTION 2. MATERIALS AND METHODS 
The accumulating cvidcIlcc concerning the biologicnl 
rclcvancc of the carbohydrate part of glycoprotcins has 
highly stimulated the intcrcst in biochemical and phar- 
maccutical aspects of these biopolymcrs [l-S]. In par- 
ticular, it has activated the discussion with respect to 
genetically engineered proteins cxprcssed in hetcrolo- 
gous cell types with or without glycosylation machinz- 
rics [4,5]. Because the cellular glycosylation machinery 
can vary among different cell !ines, different glycosyla- 
tion patterns of glycoproteins can be expected. Based 
on the present knowlecige about primacy carbohydrate 
structures of recombinant human glycoproteins, the 
Chinese hamster ovary (080) cells seem to be prefer- 
red [6]. 
Conmcrcially ;lWililblc rccoiiibinanr him11n tissue pl:l!illliIirlgcll as- 
tivntor (IPA), cxprcssc‘d in CHO cells (Astilysc), ws obtained from 
‘II~o~t~ac (Bihurilrh 011 dcr Hiss, FRO). CK-lO.ccll dcrivcd reconlbinailt 
I~uII~:I~~ rhiincric pl;~smincgcn activator (kzt~PA) was a gift of Cibn- 
Geigy Ltd (Bnscl, Switscrlnnd), CHO.scll dcrivcd recombinant 
hWal1 cryt]lro])oictin (EPO) was u gift of Organon Tckniklr 13V (Ilox. 
[cl, The Ncthcrlnnds), iuld CHO~ccll dcrivcd recombinant human 
foi]iIropin (FSH) WIS a gift of Diosynth BV (Oss, ‘Ihc Netherlands), 
Human scrotrnnsfcrrin and b0vii.e fibrinoycn wcrc obtnincd from 
Sigma. Pcptide.N’-(N-acetyl-~~-~lucosnrTlinyl)ns]~ara~i~~c alnidasc I: 
(PNGascaF) from Nuvobacfcriun~ nleningouepliclrnl wns purchased 
from Bochringcr Mannheim, 
2.2. Liberation of N4~tkcd carbollydmtc ctlmins 
In the framework of our program on the microanaly- 
sis of (recombinnnr.; glyzoprotein glycans, we have 
discovered that 0X0 cells can generate asparagine- 
linked carbohydrate chains containing N-glysolylneura- 
minic acid (NeuSGc), as illustrated here for 4 recombi- 
nant human glycoproteins. 
The N-linkedcarbohydrate chains of kztuPA and EPO were relens- 
ed by treatment with non-immobilized PNGase.F cssentialiy as 
described [9,8]. In case of EPO a complete liberation of oliposac- 
charides was obtained without the addition of Non-idet P-40, as in- 
dicated by SDS-PAGE. Released carbohydrate chains were collected 
by gel-permeation chromatography on Bio-Gel P-100 (BioRad) using 
50 mM (k2tuPA) or 25 mM (EPO) NHdHCO,, pH 9,0, as cluent. In 
each case, the pooled carbohydrate fraction was scparatcd according 
to charge by FPLC on Mono Q (Pharmacia), followed by HPLC of 
the subfractions on Lichrosorb-NH2 (Chrompack). 
2.3. Analysis of sialic acids 
Correspondence address: J.P. Kamerling, Bijvoet Center, Depart- 
ment of Bio-Organic Chemistry, Utrccht University, P.O. BOX 
80.095, NL.3508 TB Utrccht, The Netherlands 
AbDrev/arions: NeuSAc, N-acetylneuraminic acid; NeuSGc, N-gly- 
colylneuraminic acid; Fuc, fucose; CHO, Chinese hamster ovary; 
tPA, tissue plasminogen activator; katuPA, recombinant chimeric 
plasminogen activator; EPO, erythropoietin; FSI-I, follicle stimu- 
lating hormone, follitropin; hCG, human chorionic gonadotropin; 
PNGase-F, peptide-N’.(N-acetyl-P-glucosaminyl)asparagine amidase 
F; DMB, 1,2-diamino-4,5-methylene-dioxybsnzcne. 
The analysis of sialic acids was carried out essentially as described 
191. Briefly, aliquots of sialoglycoproteins (0.25-I mg) in 0.2 ml of 2 
M acetic acid were heated for 3 h at 80°C, and released sialic acids 
wereconverted with 1,2-diamino-4,5-methylene-dioxybenzene (DMB) 
into fluorescent derivatives. WAcetylneuraminic acid (NeuSAc) and 
N-glycolylneuraminic acid (NeuSGc) were used as standards. HPLC 
analysis was carried out on a Kratos Spectroflow 400 HPLC system 
equipped with a Chromspher Cls (Chrompack) reversed-phase CO]- 
t!mn (25 x 0.46 cm) and Kratos 9lsO fluorescence detector operating 
at an excitation wavelength of 393 nm, detection emission at 
wavelengths > 448 nm using a cut-off filter. Elutions were performed 
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Fig. 1. HPLC Profile of DMB derivatives of sialic acids, released 
from different glycoproteins, on a Chromspher CI~ column (25 x 
0.46 cm). The elution was carried out with acetonitrile : methanol : 
water (9 : I : 84, v/v/v) at a flow rate of 1 ml/min. (A) human 
serotransferrin; (B) bovine fibrinogen; (C) recombinant human FSPI, 
expressed in CM0 cells, 
1C the HPLC profile of the DMEi sialic acids derived 
from recombinant human FSH is presented, showing 
peaks at clution positions corresponding witfa NeuSCc 
and NeuSAc in a ratio of 3:97. Similar patterns were 
found for recombinant kztuPA, EPO, and PA. These 
findings strongly suggest that the occurrence of NcuSGc 
as a constituent of carbohydrate chains in rl;lcombinanr 
glycoprotcins expressed in not:nal CHO cells, is a 
general feature. 
3.2. Identjficarion of NeuSGc-containing N-linked 
chains in kztuPA md EPO 
The pool ot N-linked carbohydrate chains of kztuPA, 
released by PNGase-F, was separated on Mcrlo Q, 
yielding 4 carbohydrate-positive p aks (K l-N4) having 
the same retention volumes as mono-, di-, tri-, and 
tetra-sialo N-type antennary structures, respectively [8], 
Each FPLC fraction was iurther separated by HPLC 
on Lichrosorb-NHz. Tn the context of this paper, the 
WPLC subfractions N2.2 and N2.3 of FPLC fraction 
N2 (Fig. 2) will be discussed in more detail. The major 
fraction N2.2 represents the following conventional 
disialo diantennary compound: 
10 
The ‘I-I-NMK spccrrum shows the characteristic struc- 
tural reporters for the cclnstituting Gal., GlcNAc, Man 
and Fuc residues, being identical to those of 1~2.2 (see 
also [7]). However, as compared to N2.2, thca intensity 
of the NAc signal of NcuSAc at 6 = 2.031 ppm is halv- 
cd, whcrcas a new singlet at 6 = 4.121 ppm is observed, 
diagnostic for the N-glycolyl group of NcuSGc [8]. In 
addition, two sialic acid H-3e double doublets arc 
observed at d = 2.958 pprn (NeuSAc) and 6 = 2.775 
ppm (NeuSGc), whereas in the H-3a chemical-shift 
region 4 triplets occur at 6 = 1.797 ppm (Neu5Ac, 
Manaul-3 branch), 6 = 1.801 ppm (NcuSAc, Manor l-6 
branch), f = 1.813 ppm (NcuSGc, Manoll-3 branch), 
and 6 = 1.820 :?pm (NeuSGc, Mancxl-6 branch), The 
assignments of the H-3 signals arc based 0;1 comparison 
with the related signals in N2,2, and on shift increments 
going from NeuSAc to NeuSGc in ~~2-6 linked sialic- 
acid-containing diantennary str\ictures (As = + O.OlV 
0.019 ppm) [8] and in CI-!inkcd ,~iecv2-3Gnl~~l-3Gal- 
NAcc\l (H-3c, AS = i-O.013 ppm; I-l-3& A& = -i-O.017 
ppm) [13]. The rclarivc rctcntion volume of N2,3 with 
rcspcct o N2.2 is in accordance with the rcplaccmcnt of 
only one Ncu§Ac rcsiduc by NcuSGc (compnrc with the 
disialo(a2-6) diantcnnacy carbohydrate chains from 
bovine fibrinogen [8]), 
The pool of N-linked carbohydrate chains of EPO 
released by PNGasc-F VW fractionated on Mono Q, 
yielding 4 carbohydrate-positive p aks (Al-A4) at the 
same retention positions as mentioned for k2tuPA (see 
above). Each FPLC fraction was further subfrac- 
rionatcd by HYLC on Lichrosorb-NHz. In the context 
of this report, the HPLC subfractions A4.4 and A4.5 of 
FPLC fraction A4 (Fig. 3) will be discussed in more 
der.all. ‘H-NMR ana!gsis of subfraction 144.4 
demonstrated the presence of the fo!l;;wing tetrasialo 
tetraantennary compound: 
NeuS Accr%-3Gal/3 l-4GlcNAcP l-6 
NeuS AcaZ-3Galp l-4GlcNAcP I -&anol l-6 , FllCCXll-6 
, Manp l-4GlcNAcp I-4&cNAc 
Neu5Acc&3Gal/31-4GlcNAc~l-~Mancy1-3 
MeuSAcrxZ-3Galpl-4GlcNAc@l-4 
[A&4] 
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oligosaccharide from recombinant human FSH [14]. 
The four ~~2-3 linked NeuSAc residues give rise to the 
,’ characteristic set of structural reporters:at 6 = 2.031 
A.4.4 ppm (4x ‘NAc), 6 = 1.804 ppm (4 x H-3a), and 6 = 
2.756 ppm. (4 x H-3e). Comparison of the ‘H-YMR 
spectra of the subfractions A4.4 and A4.5 shows that 
the niajor component in subfraction A4.5 has the same 
characteristic structural reporters for the constituting 
Gal, GlcNAd, Man and Fuc residues as those found for 
A4.4 (see, also [14]). Howeyer, in case of A4.$ the 6- 
region covering the H-2 signal for al-6 linked Man, the 
H-3 signal of Gal (4 x), and the H-5 signal of Fuc, con- 
tains an additional singlet at 6 = 4.121 ppm,‘typical for 
the NGc signal of ‘NeuSGc [g]. As corhpared 90 the 
relative intensity of the NAc singlet of NeuSAc in the 
NAc region of the NMR spectrum of A4.4, the intensity 
of the NAc singlet in the spectrum of A4;S is reduced to 
about 75%. Furthermore, additional signals are piesent 
v- -- in the sialic acid H-3 regions, Double doublets for H-3e 
, are observed at 6 = 2.757 ppm (major, Neu5Ac) and 6 
0 60 120 (ml) 
= 2.794 ppm (minor, Neu5G@, whereas’ triplets .are 
Fig. 3. HPLC Fractionation pattern at 205 nm of the EPO FPLC detected for H-3a at S = I.804 ppm (major, Neu§Ac) 
fraction A4 on a Lichrosorb-NI-iz 10 pm column (25 X 0.46 cm). The and d = 1.821 ppm (minor, NeuSGc). Based on the 
elution was carried out isocraticaliy wirh 30 mM K~HPO+/KHZPO~, : NMR, data and the relative retention volume of A45 as 
PI-I 7.0 : acetonitrile (37.5 : 62.5, v/v) at a flow rate of 2 ml/min at 
ambient temperature. Fractions were collected as indicated. 
compared to 84.4 (&.s = 1.3 x 1p~d.4) [a], it can be 
concluded that overall one of the NeuSAc residues has 
been replaced by NeuSGc in the tetrasialo tetraanten- 
The NMR data of A4.4 are in agreemknt with those nary structure. Whether or not a specific antenna is in- 
reported for the tetrasialo(Neu5Ac(u2-3) tetraantennary volved needs to be clarified. 
Gal0 14GlcNAcBl-ZMancul -6 
(NeuSAc&3)sNeuSGcc&3 [A4.5] 
GalP II -4GlcNAcfi l -2F l-3 
@alp14GlcNAcBl-4 
4. DISCUSSION The last type compris& mono-, di-; tri-, tri’-, and tetra- 
antennary glycans. Also pslj+V-acetyllactosamin@ se- 
In view of the literature data on the recombinant quences can occur. The terminal NeuSAc residue is 
variants of human interferon-y [15], hCG f6], human always exclusively linked in (~2-3 .position to 
FSH [14], human interferon-@1 [16-183, bovine Galpl4GlcNAc, indicating the absence of O-Gal 
lutropin [ 191, human EPO [%O-221, human #A a%-6-sialyltransferase activity. It has been shown that 
[23-2>]; human transforming growth factor-@1 precur- the terminal, sialylation of N-linked glycans in CHQ 
sor [26], human immunodeficiency virus envelope cells can be altered by expresBion df this transferase 
glycoprotein gp120 [%7,28], human CD4 [29,30], and [32]. Structures with bisecting GlcMAc 1141, the anten- 
human interleukia-5 [311p it can be concluded that CM0 nary element GalNAc~l-4GlcNAc [ 191, peripheral 
cells can synthesize glycoproteins with (phosphorylated) Fuccul-3GlcNAc [33] and the antennary element Galm- 
oligomannose, hybrid, as well as IV-acetyllactosamine 1-3Gal@l-4 [4] are not produced. Recently, also the 
type of structures, depending on the- protein involved. transfection of a human al-3 fucosyltransferase gene 
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